Market Overview:
The radium-223 segment is expected to grow at the highest CAGR during the forecast period owing to its high efficacy in treating bone metastasis. The thyroid cancer segment accounted for majority of share in 2017 due to high prevalence of thyroid cancer across different regions worldwide.
Product Definition:
They are important because they allow doctors to target specific areas of the body for treatment, minimizing damage to surrounding tissue.
Radium-223:
Radium-223 is a radioactive element that can be obtained from the mineral radon. It has a very small but significant content of 223 Ra. The most common way to obtain radium-223 is by using a cyclotron; it's an electromagnetic isotope separation device where the radioactive material is separated according to its different atomic masses.
Lutetium-177:
It is a member of the platinum group metals and has an atomic number 77. Lutetium-177 has been studied extensively as an imaging agent for its ability to produce high quality images with improved contrast which makes it useful in oncology, cardiology, and neurology procedures along with being useful in medical diagnosis.
Application Insights:
The thyroid application segment accounted for the largest revenue share in 2016 and is anticipated to continue its dominance over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. In addition, increasing use of these products for medical imaging is also expected to drive regional growth over the forecast period. Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to rising healthcare expenditure and growing patient awareness about early diagnosis in emerging countries such as China and India.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related diseases such as obesity and smoking. According to the World Health Organization (WHO), there were 14 million new cases of cancer in 2012, and this number is expected to rise to 21 million by 2030. This will create a large pool of patients who will require treatment with therapeutic radiopharmaceuticals.
- Growing demand for personalized medicine: There is a growing demand for personalized medicine, which involves tailoring treatments according to the individual patient’s needs and preferences. Therapeutic radiopharmaceuticals are well suited for this type of treatment as they can be customized according to the patient’s specific tumor characteristics.
- Advances in medical imaging technology: Medical imaging technology has been making rapid advances in recent years, with new technologies such as positron emission tomography (PET) being developed all the time. This has led to an increase in demand for therapeutic radiopharmaceuticals, as these drugs can be used effectively in conjunction with medical imaging devices to help diagnose and treat tumors accurately and efficiently .
Scope Of The Report
Report Attributes
Report Details
Report Title
Therapeutic Radiopharmaceuticals Market Research Report
By Type
Radium-223, Lutetium-177, Iodine-131, Other
By Application
Thyroid, Bone Metastasis, Lymphoma, Other
By Companies
Bayer, Novartis, China Isotope & Radiation, Dongcheng, Q BioMed, Curium Pharmaceuticals, Jubilant DraxImage, Lantheus, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, International Isotopes
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Therapeutic Radiopharmaceuticals Market Report Segments:
The global Therapeutic Radiopharmaceuticals market is segmented on the basis of:
Types
Radium-223, Lutetium-177, Iodine-131, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Thyroid, Bone Metastasis, Lymphoma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Novartis
- China Isotope & Radiation
- Dongcheng
- Q BioMed
- Curium Pharmaceuticals
- Jubilant DraxImage
- Lantheus
- Spectrum Pharmaceuticals
- Progenics Pharmaceuticals
- International Isotopes
Highlights of The Therapeutic Radiopharmaceuticals Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radium-223
- Lutetium-177
- Iodine-131
- Other
- By Application:
- Thyroid
- Bone Metastasis
- Lymphoma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Therapeutic Radiopharmaceuticals Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Therapeutic radiopharmaceuticals are medications that use radiation to treat cancer. They can be used in a variety of ways, including as part of surgery or chemotherapy. Therapeutic radiopharmaceuticals can also be used to help destroy cancer cells outside the body.
Some of the major companies in the therapeutic radiopharmaceuticals market are Bayer, Novartis, China Isotope & Radiation, Dongcheng, Q BioMed, Curium Pharmaceuticals, Jubilant DraxImage, Lantheus, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, International Isotopes.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Therapeutic Radiopharmaceuticals Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Therapeutic Radiopharmaceuticals Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Therapeutic Radiopharmaceuticals Market - Supply Chain
4.5. Global Therapeutic Radiopharmaceuticals Market Forecast
4.5.1. Therapeutic Radiopharmaceuticals Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Therapeutic Radiopharmaceuticals Market Size (000 Units) and Y-o-Y Growth
4.5.3. Therapeutic Radiopharmaceuticals Market Absolute $ Opportunity
5. Global Therapeutic Radiopharmaceuticals Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Type
5.3.1. Radium-223
5.3.2. Lutetium-177
5.3.3. Iodine-131
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Therapeutic Radiopharmaceuticals Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Application
6.3.1. Thyroid
6.3.2. Bone Metastasis
6.3.3. Lymphoma
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Therapeutic Radiopharmaceuticals Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Therapeutic Radiopharmaceuticals Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Therapeutic Radiopharmaceuticals Demand Share Forecast, 2019-2026
9. North America Therapeutic Radiopharmaceuticals Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Application
9.4.1. Thyroid
9.4.2. Bone Metastasis
9.4.3. Lymphoma
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Type
9.7.1. Radium-223
9.7.2. Lutetium-177
9.7.3. Iodine-131
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Therapeutic Radiopharmaceuticals Demand Share Forecast, 2019-2026
10. Latin America Therapeutic Radiopharmaceuticals Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Application
10.4.1. Thyroid
10.4.2. Bone Metastasis
10.4.3. Lymphoma
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Type
10.7.1. Radium-223
10.7.2. Lutetium-177
10.7.3. Iodine-131
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Therapeutic Radiopharmaceuticals Demand Share Forecast, 2019-2026
11. Europe Therapeutic Radiopharmaceuticals Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Application
11.4.1. Thyroid
11.4.2. Bone Metastasis
11.4.3. Lymphoma
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Type
11.7.1. Radium-223
11.7.2. Lutetium-177
11.7.3. Iodine-131
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Therapeutic Radiopharmaceuticals Demand Share, 2019-2026
12. Asia Pacific Therapeutic Radiopharmaceuticals Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Application
12.4.1. Thyroid
12.4.2. Bone Metastasis
12.4.3. Lymphoma
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Type
12.7.1. Radium-223
12.7.2. Lutetium-177
12.7.3. Iodine-131
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Therapeutic Radiopharmaceuticals Demand Share, 2019-2026
13. Middle East & Africa Therapeutic Radiopharmaceuticals Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Application
13.4.1. Thyroid
13.4.2. Bone Metastasis
13.4.3. Lymphoma
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Therapeutic Radiopharmaceuticals Market Size and Volume Forecast by Type
13.7.1. Radium-223
13.7.2. Lutetium-177
13.7.3. Iodine-131
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Therapeutic Radiopharmaceuticals Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Therapeutic Radiopharmaceuticals Market: Market Share Analysis
14.2. Therapeutic Radiopharmaceuticals Distributors and Customers
14.3. Therapeutic Radiopharmaceuticals Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. China Isotope & Radiation
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Dongcheng
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Q BioMed
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Curium Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Jubilant DraxImage
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Lantheus
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Spectrum Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Progenics Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. International Isotopes
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
